Lynparza (olaparib) : novo tarčno zdravilo pri raku jajčnikov

Show document
A+ | A- | | SLO | ENG

Title:	Lynparza (olaparib) : novo tarčno zdravilo pri raku jajčnikov
Authors:	ID Škof, Erik (Author) ID Krajc, Mateja (Author)
Files:	PDF - Presentation file, download (455,09 KB)
Language:	Slovenian
Typology:	1.04 - Professional Article
Organization:	OI - Institute of Oncology
Keywords:	rak jajčnikov, tarčna zdravila, kemoterapija, dedni raki
Publication status:	Published
Publication version:	Version of Record
Year of publishing:	2016
Number of pages:	str. 12-14
Numbering:	Letn. 20, št. 1
COBISS.SI-ID:	2416763
UDC:	618.1
ISSN on article:	1408-1741
Publication date in DiRROS:	03.01.2018
Views:	718
Downloads:	20
Metadata:
:	Copy citation

Share:

Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Title:	Onkologija. strokovni časopis za zdravnike
Shortened title:	Onkologija
Publisher:	Onkološki inštitut
ISSN:	1408-1741
COBISS.SI-ID:	65324032

Language:	English
Title:	Lynparza (olaparib) : New Mmedicine for targeted therapy of ovarian cancer
Abstract:	A new medicine for targeted treatment of patients with recurring serous ovarian or primary peritoneal serous carcinoma (PPSC), who have a mutation of BRCA1/2 genes (somatic mutation), was recently registered in the EU – LynparzaTM (olaparib). Olaparib was registered based on a subanalysis of a study in phase II (9), in which patients with BRCA1/2 gene mutation who received olaparib lived 7 months longer without the disease progressing than patients that were not administered this medicine (11 months vs. 4 months); the difference was statistically relevant (HR 0.18; p < 0.00001). There were no differences in total survival of patients. Olaparib is an oral medication in capsules, so patients can take it at home. The available data shows that the most frequent side effects were nausea and fatigue. 25% of patients took olaparib for two years or more and the therapy was rarely discontinued due to side effects (only 9% of patients), which shows that patients usually tolerate olaparib well, which is a great advantage compared to chemotherapy, which was so far the only available treatment for recurring ovarian cancer (9).

This document is a part of these collections:

Back